- Home
- CSHR vs NGNE Comparison
CSHR vs NGNE Comparison
Compare CSHR & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CSHR | NGNE |
|---|---|---|
| Founded | N/A | 2003 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 764.3M | 744.9M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CSHR | NGNE |
|---|---|---|
| Price | $5.36 | $35.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $63.57 |
| AVG Volume (30 Days) | 186.6K | ★ 195.8K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.51 | $15.93 |
| 52 Week High | $6.29 | $43.66 |
Technical Indicators
Market Signals| Indicator | CSHR | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 46.58 |
| Support Level | $3.99 | $35.26 |
| Resistance Level | $5.46 | $42.84 |
| Average True Range (ATR) | 0.36 | 2.53 |
| MACD | -0.11 | -0.23 |
| Stochastic Oscillator | 8.44 | 12.74 |
Price Performance
Historical ComparisonAbout CSHR CoinShares PLC Ordinary Shares
CoinShares PLC is the European digital asset manager that delivers a broad range of financial services across investment management, trading, and securities to a wide array of clients that include corporations, financial institutions, and individuals.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.